Brief: Abbisko Cayman Says FDA Grants Orphan Drug Designation To Abbisko's Absk061 For Achondroplasia
19/03/2026 01:20
March 19 (Reuters) - Abbisko Cayman Ltd 2256.HK: FDA GRANTS ORPHAN DRUG DESIGNATION TO ABBISKO'S ABSK061 FOR ACHONDROPLASIA Further company coverage: 2256.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly